Precision medicine cloud software specialist Genospace is to be merged into Sarah Cannon, the global cancer institute of Hospital Corporation of America (HCA), and will operate as a Sarah Cannon subsidiary. The firms say the merger will enable the more effective use of molecular profiling data to match cancer patients to clinical trials. Terms of the deal were not disclosed, but the transaction is expected to close during Q1 2017.

Genospace has developed a suite of software tools to enable the interpretation, analysis, and application of genomic and other biomedical data in research and clinical care. Following the merger into Sarah Cannon, the firm will retain its Cambridge, MA, headquarters and lead development of a cloud-based system to that will allow the analysis of disparate data from clinical and laboratory sources across patient populations. The platform will be leveraged by Sarah Cannon oncology programs in the U.S. and U.K. “Genospace’s innovative technology approach to understanding each patient’s cancer directly supports our strategic goal of personalizing care delivery,” said Jonathan B. Perlin, M.D., Ph.D., MSHA, MACP, FACMI, president, clinical services and chief medical officer at HCA. “By tailoring treatments based on the unique genetic makeup of a patient’s cancer, we can more effectively treat the disease.”

“As genomic information advances, it is crucial that oncologists and researchers have rapid access to an efficient and nimble technology solution for interpreting molecular data and guiding clinical decision making,” added Howard A. “Skip” Burris III, M.D., president, clinical operations and chief medical officer at Sarah Cannon. “Genospace’s leadership in this field will help us to transform the way we gather and analyze genomic information, resulting in better identification of effective treatment options for our patients.”

In October 2016 Genospace launched Genospace Trial Match, a mobile application that allows physicians to match patients to clincal trials that are enrolling patients, in real time, on the basis of their molecular profiling and clinical data.

Previous articleOrthocell and J&J Partner on Ortho-ATI Autologous Cell Therapy
Next articleBiogen Hemophilia Spinoff Bioverativ Begins Trading Shares